CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
Table 1
Clinical characteristics of patients with NMOSD and MS.
Clinical characteristics
NMOSD
MS (n=12)
AQP4 Ab+ (n=25)
MOG Ab+ (n=8)
Seronegative (n=16)
Sex ratio, F (%)
24(96.0)
3(37.5)
11(68.8)
9(75.0)
Age, years, mean (SD)
44.7(17.0)
38.3(8.5)
42.1(11.4)
37.4(16.0)
Disease duration, months, mean (SD)
18.9(8.8)
13.3(8.7)
16.0(10.4)
22.4(7.3)
Site of the lesions, n (%)
Optic nerve
15(60.0)
3(37.5)
7(43.6)
3(25.0)
Spinal cord
25(100.0)
6(75.0)
14(87.5)
7(58.3)
Cerebrum
11(44.0)
7(87.5)
8(50.0)
6(50.0)
Brainstem
13(52.0)
5(62.5)
10(62.5)
4(33.3)
EDSS, median (range)
6.5(2.0-8.5)
4.3(3.5-7.0)
6.3(2.5-8.0)
3.5(2.0-5.0)
CSF analysis at attack
CSF WBC count, mean (SD), /ul
19.0(24.3)
32.0(47.8)
10.3(15.7)
9.7(10.7)
CSF protein level, mean (SD), mg/dl
47.8(26.8)
42.4(16.9)
39.0(20.0)
37.4(23.7)
CSF IgG index, mean (SD)
0.6(0.2)
1.1(1.6)
0.5(0.1)
0.6(0.3)
Positive oligoclonal bands, n (%)
15(60.0)
3(37.5)
9(56.3)
8(66.7)
Continuous variables are shown as the means (SD), and categorical variables are described as percentages. NMOSD, neuromyelitis optica spectrum disorder; AQP4 Ab+, aquaporin-4 antibody positive NMOSD; MOG-Ab+, myelin-oligodendrocyte glycoprotein antibody positive NMOSD; MS, multiple sclerosis; F, female; EDSS, Expanded Disability Status Scale; CSF, cerebrospinal fluid; WBC, white blood cell.
